BRPI0713421A2 - Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero - Google Patents
Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero Download PDFInfo
- Publication number
- BRPI0713421A2 BRPI0713421A2 BRPI0713421-5A BRPI0713421A BRPI0713421A2 BR PI0713421 A2 BRPI0713421 A2 BR PI0713421A2 BR PI0713421 A BRPI0713421 A BR PI0713421A BR PI0713421 A2 BRPI0713421 A2 BR PI0713421A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- antibody
- methods
- liofolized
- liophilization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
FORMULAçãO LIOFILIZADA, FORMULAçãO AQUOSA ADEQUADA PARA A LIOFILIZAçãO, E, MéTODOS PARA ESTABILIZAR UM ANTICORPO E PARA TRATAR UM MAMìFERO. Em uma forma de realização, a presente invenção fornece uma formulação liofilizada estável que compreende um anticorpo anti-EGFR, preferivelmente cetuximab; ácido lactobiónico; e um tampão, preferivelmente histidina. Em uma forma de realização preferida, a presente invenção fornece uma formulação liofilizada estável que compreende cerca de 50 mg/ml a cerca de 140 mg/ml de ERBITUX?, cerca de 0,125% de ácido lactobiónico, cerca de 25 mM de tampão de histidina em um pH de cerca de 6,0, cerca de 0,005% de Tween 80 e cerca de 1,875% de glicina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81395806P | 2006-06-14 | 2006-06-14 | |
US60/813958 | 2006-06-14 | ||
PCT/US2007/071119 WO2007147001A2 (en) | 2006-06-14 | 2007-06-13 | Lyophilized formulations of anti-egfr antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0713421A2 true BRPI0713421A2 (pt) | 2012-03-13 |
Family
ID=38832820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0713421-5A BRPI0713421A2 (pt) | 2006-06-14 | 2007-06-13 | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100158925A1 (pt) |
EP (1) | EP2029163A4 (pt) |
JP (1) | JP2009540015A (pt) |
KR (1) | KR20090021298A (pt) |
CN (1) | CN101466404A (pt) |
AU (1) | AU2007260769A1 (pt) |
BR (1) | BRPI0713421A2 (pt) |
CA (1) | CA2654794A1 (pt) |
CR (1) | CR10493A (pt) |
EA (1) | EA200870538A1 (pt) |
EC (1) | ECSP088962A (pt) |
IL (1) | IL195794A0 (pt) |
MA (1) | MA30515B1 (pt) |
MX (1) | MX2008015852A (pt) |
NO (1) | NO20085131L (pt) |
TN (1) | TNSN08511A1 (pt) |
WO (1) | WO2007147001A2 (pt) |
ZA (1) | ZA200810456B (pt) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
US8524233B2 (en) | 2008-03-14 | 2013-09-03 | Biocon Limited & Centro de Immunologia Molecular | Monoclonal antibody and a method thereof |
CN101716343A (zh) * | 2008-10-09 | 2010-06-02 | 哈药集团生物工程有限公司 | 一种单克隆抗体的冻干制剂 |
FR2944448B1 (fr) * | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
PT3721904T (pt) * | 2009-11-20 | 2021-11-15 | Biocon Ltd | Formulações de anticorpo t1h |
FR2958646B1 (fr) | 2010-04-07 | 2012-05-18 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe. |
AU2010338305A1 (en) * | 2009-12-29 | 2012-05-24 | F. Hoffmann-La Roche Ag | Antibody formulation |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
CA3101298A1 (en) | 2010-03-01 | 2011-09-09 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
CN103108658B (zh) * | 2010-07-02 | 2015-08-19 | 米迪缪尼有限公司 | 抗体制剂 |
UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
DK3024485T3 (da) | 2013-07-23 | 2020-12-07 | Biocon Ltd | Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå |
CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
CN104341505A (zh) * | 2013-07-29 | 2015-02-11 | 西藏海思科药业集团股份有限公司 | 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体 |
EP3044236A2 (en) * | 2013-09-12 | 2016-07-20 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
CN107108738A (zh) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法 |
TW201618774A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用btk抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
EP3110447B1 (en) * | 2014-09-16 | 2020-04-29 | Synermore Biologics Co., Ltd. | Anti-egfr antibody and uses of same |
CN105435221B (zh) * | 2014-09-22 | 2021-09-28 | 正大天晴药业集团股份有限公司 | 一种针对血管内皮生长因子的人源化抗体的药物组合物 |
WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
KR20230149328A (ko) * | 2014-12-22 | 2023-10-26 | 시스트이뮨, 인코포레이티드 | 이중특이적 4가 항체 및 이의 제조 및 사용방법 |
KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
JP6890602B2 (ja) | 2015-11-06 | 2021-06-18 | アセルタ ファーマ ビー.ブイ. | ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤 |
DK3529274T3 (da) | 2016-10-21 | 2024-06-17 | Biocon Ltd | Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus |
BR112019013202A2 (pt) * | 2016-12-28 | 2019-12-10 | Japan Chem Res | formulação liofilizada |
US11639391B2 (en) * | 2017-04-18 | 2023-05-02 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
WO2019075405A1 (en) | 2017-10-14 | 2019-04-18 | Cytomx Therapeutics, Inc. | ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF |
CN112512583B (zh) * | 2018-06-01 | 2023-11-14 | 乐天医药生技股份有限公司 | 酞菁染料偶联物组合物 |
CN110960490A (zh) * | 2018-09-28 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种抗egfr抗体偶联药物组合物及其用途 |
US11498969B2 (en) | 2019-01-31 | 2022-11-15 | Sanofi Biotechnology | Compositions and methods for treating juvenile idiopathic arthritis |
CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
EP3980131A4 (en) * | 2019-06-06 | 2023-06-28 | Janux Therapeutics, Inc. | Compositions and methods relating to tumor activated t cell engagers |
CU20190104A7 (es) * | 2019-12-17 | 2021-08-06 | Ct Inmunologia Molecular | Formulación estable del anticuerpo nimotuzumab |
JP2023547978A (ja) | 2020-08-11 | 2023-11-15 | ジャナックス セラピューティクス,インク. | 切断可能リンカー組成物および方法 |
WO2022125576A1 (en) | 2020-12-09 | 2022-06-16 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
KR20230118167A (ko) * | 2020-12-11 | 2023-08-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 다목적 적용을 위한 제형 |
IL311698A (en) * | 2021-10-03 | 2024-05-01 | Systimmune Inc | Cancer treatment methods and preparations and medicines for this |
WO2024058201A1 (ja) * | 2022-09-16 | 2024-03-21 | 国立研究開発法人量子科学技術研究開発機構 | 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62158160A (ja) * | 1985-12-27 | 1987-07-14 | 堺化学工業株式会社 | 成形触媒及び接触反応方法 |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6695940B2 (en) * | 2001-04-05 | 2004-02-24 | Alan D. Devoe | Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
EP1735348B1 (en) * | 2004-03-19 | 2012-06-20 | Imclone LLC | Human anti-epidermal growth factor receptor antibody |
CA2642270A1 (en) * | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Antibody formulation |
-
2007
- 2007-06-13 BR BRPI0713421-5A patent/BRPI0713421A2/pt not_active IP Right Cessation
- 2007-06-13 MX MX2008015852A patent/MX2008015852A/es unknown
- 2007-06-13 US US12/308,451 patent/US20100158925A1/en not_active Abandoned
- 2007-06-13 WO PCT/US2007/071119 patent/WO2007147001A2/en active Application Filing
- 2007-06-13 KR KR1020087032258A patent/KR20090021298A/ko not_active Application Discontinuation
- 2007-06-13 CA CA002654794A patent/CA2654794A1/en not_active Abandoned
- 2007-06-13 EP EP07798508A patent/EP2029163A4/en not_active Withdrawn
- 2007-06-13 CN CNA2007800221784A patent/CN101466404A/zh active Pending
- 2007-06-13 AU AU2007260769A patent/AU2007260769A1/en not_active Abandoned
- 2007-06-13 EA EA200870538A patent/EA200870538A1/ru unknown
- 2007-06-13 JP JP2009515628A patent/JP2009540015A/ja not_active Withdrawn
-
2008
- 2008-12-08 IL IL195794A patent/IL195794A0/en unknown
- 2008-12-09 NO NO20085131A patent/NO20085131L/no not_active Application Discontinuation
- 2008-12-10 ZA ZA200810456A patent/ZA200810456B/xx unknown
- 2008-12-11 TN TNP2008000511A patent/TNSN08511A1/en unknown
- 2008-12-11 CR CR10493A patent/CR10493A/es not_active Application Discontinuation
- 2008-12-11 EC EC2008008962A patent/ECSP088962A/es unknown
- 2008-12-12 MA MA31475A patent/MA30515B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MA30515B1 (fr) | 2009-06-01 |
CR10493A (es) | 2009-02-26 |
ECSP088962A (es) | 2009-01-30 |
AU2007260769A1 (en) | 2007-12-21 |
ZA200810456B (en) | 2009-12-30 |
EP2029163A2 (en) | 2009-03-04 |
CN101466404A (zh) | 2009-06-24 |
US20100158925A1 (en) | 2010-06-24 |
KR20090021298A (ko) | 2009-03-02 |
IL195794A0 (en) | 2011-08-01 |
EA200870538A1 (ru) | 2009-04-28 |
MX2008015852A (es) | 2009-02-23 |
NO20085131L (no) | 2009-03-13 |
JP2009540015A (ja) | 2009-11-19 |
TNSN08511A1 (en) | 2010-04-14 |
EP2029163A4 (en) | 2010-08-11 |
CA2654794A1 (en) | 2007-12-21 |
WO2007147001A2 (en) | 2007-12-21 |
WO2007147001A3 (en) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0713421A2 (pt) | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero | |
BRPI0514340A (pt) | formulações de estabilização | |
PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
EA200970880A1 (ru) | Стабильные композиции на основе антител | |
BRPI0818765A8 (pt) | Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo | |
PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
EA201001204A1 (ru) | Методы и композиции, в которых применяют слитые полипептиды klotho-fgf | |
BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
GT200600115A (es) | Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal | |
BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
ECSP10010697A (es) | Inhibidores de dpp-iv para uso en el tratamiento de nafld | |
TW200621804A (en) | Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
RU2010131179A (ru) | Жидкая композиция, содержащая антитело высокой концентрации | |
BRPI0516408B8 (pt) | derivados de estilbeno e seu uso para ligação e formação de imagem de placas de amilóide | |
CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
EA201100072A1 (ru) | Новые композиции и способы | |
BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
BRPI0607084A2 (pt) | uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto | |
BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
EA201001749A1 (ru) | Способ лечения недифференцированного артрита | |
BRPI0720230A2 (pt) | Uso de uma formulação nutricional oralmente administrável, formulação nutricional, método para tratar um distúrbio desenvolvimental penetrante, e, composição | |
MA32183B1 (fr) | Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt | |
ATE358992T1 (de) | Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: IMCLONE LLC (US) Free format text: NOME ALTERADO DE: IMCLONE SYSTEMS INCORPORATED |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE. |